MDMB-FUBICA
MDMB-FUBICA is an indole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB1 receptor and has been sold online as a designer drug.
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C23H25FN2O3 |
| Molar mass | 396.462 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
It was first detected by the EMCDDA in Sweden in February 2015.[1] It is often sold in e-liquid form for use in an electronic cigarette.[2]
Side effects
MDMB-FUBICA's indazole analogue MDMB-FUBINACA has been linked to at least 1000 hospitalisations and 40 deaths as a consequence of intoxication as of March 2015.[3]
Legality
MDMB-FUBICA is banned in Sweden.[4]
See also
References
- "Hamarosan: 2015. Évi Európai Kábítószer - Jelentés" (PDF). Hungarian National Focal Point (NFP). June 2015. Retrieved 23 July 2015.
- Peace MR, Krakowiak RI, Wolf CE, Poklis A, Poklis JL (February 2017). "Identification of MDMB-FUBINACA in commercially available e-liquid formulations sold for use in electronic cigarettes". Forensic Science International. 271: 92–97. doi:10.1016/j.forsciint.2016.12.031. PMC 5511053. PMID 28076838.
- "Очередная жертва спайса". Federal Drug Control Service of the Russian Federation. 17 March 2015. Archived from the original on 14 July 2015. Retrieved 24 July 2015.
- "23 nya ämnen kan klassas som narkotika eller hälsofarlig vara". Folkhälsomyndigheten. 1 June 2015. Retrieved 24 July 2015.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.